ALLMedicine™ Angioimmunoblastic Lymphoma Center
Research & Reviews 18 results
https://clinicaltrials.gov/ct2/show/NCT05313243
Jul 26th, 2022 - CD30- Positive Peripheral T cell (PTCL) and Cutaneous T cell Lymphomas (CTCL): T-cell Non-Hodgkin Lymphoma (NHL) includes a clinically heterogeneous group of mature T-cell lymphomas accounting for 10-12% of all NHL. Peripheral T- cell Lymphoma (PT...
https://emedicine.medscape.com/article/203399-overview
Aug 3rd, 2021 - Practice Essentials Non-Hodgkin lymphomas (NHLs) are tumors originating from lymphoid tissues, mainly of lymph nodes. These tumors may result from chromosomal translocations, infections, environmental factors, immunodeficiency states, and chronic ...
http://emedicine.medscape.com/article/203399-overview
Aug 3rd, 2021 - Practice Essentials Non-Hodgkin lymphomas (NHLs) are tumors originating from lymphoid tissues, mainly of lymph nodes. These tumors may result from chromosomal translocations, infections, environmental factors, immunodeficiency states, and chronic ...
https://emedicine.medscape.com/article/203399-print
Aug 3rd, 2021 - Practice Essentials Non-Hodgkin lymphomas (NHLs) are tumors originating from lymphoid tissues, mainly of lymph nodes. These tumors may result from chromosomal translocations, infections, environmental factors, immunodeficiency states, and chronic ...
https://emedicine.medscape.com/article/203399-
Aug 3rd, 2021 - Practice Essentials Non-Hodgkin lymphomas (NHLs) are tumors originating from lymphoid tissues, mainly of lymph nodes. These tumors may result from chromosomal translocations, infections, environmental factors, immunodeficiency states, and chronic ...
Clinicaltrials.gov 2 results
https://clinicaltrials.gov/ct2/show/NCT05313243
Jul 26th, 2022 - CD30- Positive Peripheral T cell (PTCL) and Cutaneous T cell Lymphomas (CTCL): T-cell Non-Hodgkin Lymphoma (NHL) includes a clinically heterogeneous group of mature T-cell lymphomas accounting for 10-12% of all NHL. Peripheral T- cell Lymphoma (PT...
https://clinicaltrials.gov/ct2/show/NCT00785330
Jan 13th, 2020 - Patients in the age of 18 to 65 years with a high- risk relapse of a histology proven aggressive Non-Hodgkin's-lymphoma are eligible for the trial. Aggressive Non-Hodgkin's lymphoma within this study is defined as: B-NHL: follicular lymphoma grade...
